Vibeke Hatorp

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

B. Elbrønd, Grethe Jakobsen, Søren Erik Larsen et al. · Diabetes Care · 2002 · 282 citations · Full text

Influence of Drugs Interacting with CYP3A4 on the Pharmacokinetics, Pharmacodynamics, and Safety of the Prandial Glucose Regulator Repaglinide

Vibeke Hatorp, Kristian T. Hansen, Mikael S. Thomsen · The Journal of Clinical Pharmacology · 2003 · 106 citations

Healthy Subjects, Pharmacotherapy, Insulin Signaling +16

Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment

Svenja Schumacher, I. Abbasi, Dale W. Weise et al. · European Journal of Clinical Pharmacology · 2001 · 94 citations

Chronic Kidney Disease, Pharmacology, Diabetes +9

Absorption, metabolism and excretion of a single oral dose of 14 C-repaglinide during repaglinide multiple dosing

P. N. M. van Heiningen, Vibeke Hatorp, Karin Kramer Nielsen et al. · European Journal of Clinical Pharmacology · 1999 · 82 citations

Therapeutic Drug Monitoring, Repaglinide Multiple Dosing, Pharmacology +6

Repaglinide pharmacokinetics in healthy young adult and elderly subjects

Vibeke Hatorp, W. C. Huang, Poul Strange · Clinical Therapeutics · 1999 · 67 citations

Medicine, Repaglinide Pharmacokinetics, Pharmacotherapy +2